Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. VSTM
stocks logo

VSTM

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.548
-58.81%
--
--
-0.560
-41.67%
--
--
-0.517
+32.48%
Estimates Revision
The market is revising Upward the revenue expectations for Verastem, Inc. (VSTM) for FY2025, with the revenue forecasts being adjusted by 66.76% over the past three months. During the same period, the stock price has changed by -1.58%.
Revenue Estimates for FY2025
Revise Upward
up Image
+66.76%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+20.63%
In Past 3 Month
Stock Price
Go Down
down Image
-1.58%
In Past 3 Month
Wall Street analysts forecast VSTM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VSTM is 15.50 USD with a low forecast of 14.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast VSTM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VSTM is 15.50 USD with a low forecast of 14.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 10.600
sliders
Low
14.00
Averages
15.50
High
20.00
Current: 10.600
sliders
Low
14.00
Averages
15.50
High
20.00
Mizuho
Outperform
maintain
$15
2025-11-04
Reason
Mizuho
Price Target
$15
2025-11-04
maintain
Outperform
Reason
Mizuho reiterated an Outperform rating and $15 price target on Verastem, noting the shares are falling intraday following the company's Q3 results. At first blush, the firm was "thoroughly impressed" by the first full quarterly sales of lead asset Avmapki Fakzynja/AF Co-Pack of $11.2M, which came in handily ahead of the firm's and Bloomberg's consensus estimates. Mizuho said that it believes the stock weakness is related to two updates, namely a need to add 29 additional patients to the confirmatory Phase 3 RAMP 301 study for AF and uncertainty on the timing of AF's potential inclusion in updated National Comprehensive Cancer Network treatment guidelines. The firm added that the current weakness appears overdone and recommends being "opportunistic."
Mizuho
NULL -> Outperform
maintain
$14 -> $15
2025-10-29
Reason
Mizuho
Price Target
$14 -> $15
2025-10-29
maintain
NULL -> Outperform
Reason
Mizuho raised the firm's price target on Verastem to $15 from $14 and keeps an Outperform rating on the shares.
RBC Capital
Outperform
maintain
$13
2025-10-20
Reason
RBC Capital
Price Target
$13
2025-10-20
maintain
Outperform
Reason
RBC Capital keeps an Outperform rating on Verastem with a $13 price target after the company's partner GenFleet Therapeutics reported Phase I/II data for VS-7375 outside of China in advanced pancreatic ductal adenocarcinoma patients with a KRAS G12D mutation. The data show meaningful efficacy in a highly refractory patient population, the analyst tells investors in a research note. The firm says that while VS-7375's response rate of 41% "look best-in-class," they did did decrease somewhat from the prior readout. They data overall are "still impressive," contends RBC. Verastem shares in midday trading are down 13% to $8.01.
Cantor Fitzgerald
Eric Schmidt
Overweight
initiated
$15
2025-10-16
Reason
Cantor Fitzgerald
Eric Schmidt
Price Target
$15
2025-10-16
initiated
Overweight
Reason
Cantor Fitzgerald analyst Eric Schmidt assumed coverage of Verastem with an Overweight rating and no price target. The company is developing and commercializing drugs for Ras-driven cancers, the analyst tells investors in a research note. The firm thinks the shares are worth $15 based on a sum-of-the-parts valuation. The company's avutometinib and defactinib looks like a better and more tolerable drug than the MEK inhibitors that are used off-label in recurrent low-grade serous ovarian cancer, contends Cantor.
Leerink
Jonathan Chang
Outperform
maintain
2025-09-08
Reason
Leerink
Jonathan Chang
Price Target
2025-09-08
maintain
Outperform
Reason
Leerink analyst Jonathan Chang says that following Verastem (VSTM)/GenFleet's interim data presentation for their KRAS G12D inhibitor program, the firm continues to view Revolution Medicines' (RVMD) zoldonrasib as well-positioned in the competitive landscape. Leerink notes that Outperform-rated Revolution is evaluating zoldonrasib in several Phase I/II trials. Separately, the firm hosted a pulse call with a MEDACorp NSCLC key opinion leader that, among other topics, discussed this data readout and its readthrough to Revolution's programs. At a high level, its MEDACorp KOL was encouraged by the response rate shown by VS-7475/GFH375, but they also acknowledged the caveat that the number of patients reported in the study is still small, making it difficult to compare trials from this limited patient population. Taken together, Leerink sees this update as supportive of the KRAS G12D inhibitor class as a whole and as continuing to position zoldonrasib favorably within the competitive landscape in NSCLC.
Mizuho
Outperform
downgrade
$16 -> $14
2025-08-15
Reason
Mizuho
Price Target
$16 -> $14
2025-08-15
downgrade
Outperform
Reason
Mizuho lowered the firm's price target on Verastem to $14 from $16 primarily due to dilution from an April financing, while keeping an Outperform rating on the shares. The firm notes the company reported Q2 results last week, where key takeaways, in its view, were a revenue beat for recently launched Avmapki Fakzynja Co-pack/AFC; already, reimbursement for AFC use off-label in patients who are KRAS-wild-type; an October review for AFC's potential inclusion in NCCN guidelines; and all other pipeline programs remaining on track.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Verastem Inc (VSTM.O) is -5.06, compared to its 5-year average forward P/E of -5.22. For a more detailed relative valuation and DCF analysis to assess Verastem Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.22
Current PE
-5.06
Overvalued PE
2.26
Undervalued PE
-12.70

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.17
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.42
Undervalued EV/EBITDA
-0.75

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
650.93
Current PS
0.00
Overvalued PS
2433.06
Undervalued PS
-1131.20
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 1120.13% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

VSTM News & Events

Events Timeline

(ET)
2025-11-14
09:18:10
Verastem Prices 8.544 Million Share Spot Secondary Offering at $7.25
select
2025-11-14
06:33:21
Verastem Prices 8.544 Million Share Spot Secondary Offering at $8.25
select
2025-11-13 (ET)
2025-11-13
16:15:26
Verastem Reveals Common Stock Offering, Amount Not Disclosed
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-14Benzinga
Red Cat Reports Disappointing Q3 Results, Alongside StubHub, WhiteFiber, and Other Major Stocks Declining in Friday's Pre-Market Trading

  • U.S. Stock Market Trends: U.S. stock futures are down, with Dow futures dropping approximately 100 points on Friday morning.

  • Red Cat Holdings Performance: Red Cat Holdings Inc. shares fell 15.1% in pre-market trading after reporting disappointing third-quarter results, with revenue of $9.65 million and a loss of 16 cents per share, both missing analyst expectations.

  • Other Stocks Declining: Several other companies also saw significant pre-market declines, including TSS Inc. (-40.2%), StubHub Holdings Inc. (-18.8%), and WhiteFiber Inc. (-13.4%), all reporting worse-than-expected financial results.

  • Market Reactions: The overall market is reacting negatively to various companies' earnings reports, leading to notable drops in stock prices across multiple sectors.

[object Object]
Preview
9.0
11-14NASDAQ.COM
TEM Enhances Its Leadership in Genomics with New Product Launches

  • Tempus AI Developments: Tempus AI has received FDA clearance for its xR IVD assay and launched the xM liquid biopsy assay for monitoring treatment response, while also developing a companion diagnostic test with Verastem Oncology for ovarian cancer treatment.

  • Exact Sciences Launches New Tests: Exact Sciences introduced its Cancerguard multi-cancer early detection test and the Oncodetect molecular residual disease test, both aimed at improving cancer detection and treatment personalization.

  • Guardant Health Innovations: Guardant Health expanded its Shield test for multi-cancer detection and received new companion diagnostic approvals, while also launching a hereditary cancer test and enhancing its molecular profiling assay.

  • Stock Performance and Outlook: Tempus AI shares have increased by 20% over the past year, outperforming industry growth, and the company is expected to introduce a whole-genome sequencing test next year, with positive estimates for its financial performance.

[object Object]
Preview
3.0
11-12NASDAQ.COM
Putting the Pieces Together: FESM May Have a Value of $44

  • Fidelity Enhanced Small Cap ETF Analysis: The Fidelity Enhanced Small Cap ETF (FESM) has an implied analyst target price of $44.33 per unit, indicating an 18.97% upside from its recent trading price of $37.26.

  • Notable Holdings with Upside Potential: Key underlying holdings of FESM, such as Verastem Inc (VSTM), Peloton Interactive Inc (PTON), and HUT 8 CORP (HUT), show significant upside potential based on analyst target prices, with VSTM having a target of $16.00 (89.35% upside), PTON at $10.82 (44.90% upside), and HUT at $55.44 (26.25% upside).

  • Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets relative to current prices could lead to potential downgrades if they are based on outdated information.

  • Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of the analysts' targets in light of recent company and industry developments.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Verastem Inc (VSTM) stock price today?

The current price of VSTM is 10.6 USD — it has increased 5.37 % in the last trading day.

arrow icon

What is Verastem Inc (VSTM)'s business?

Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.

arrow icon

What is the price predicton of VSTM Stock?

Wall Street analysts forecast VSTM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VSTM is 15.50 USD with a low forecast of 14.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Verastem Inc (VSTM)'s revenue for the last quarter?

Verastem Inc revenue for the last quarter amounts to 11.24M USD, decreased % YoY.

arrow icon

What is Verastem Inc (VSTM)'s earnings per share (EPS) for the last quarter?

Verastem Inc. EPS for the last quarter amounts to -1.35 USD, increased 125.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Verastem Inc (VSTM)'s fundamentals?

The market is revising Upward the revenue expectations for Verastem, Inc. (VSTM) for FY2025, with the revenue forecasts being adjusted by 66.76% over the past three months. During the same period, the stock price has changed by -1.58%.
arrow icon

How many employees does Verastem Inc (VSTM). have?

Verastem Inc (VSTM) has 78 emplpoyees as of December 05 2025.

arrow icon

What is Verastem Inc (VSTM) market cap?

Today VSTM has the market capitalization of 797.64M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free